Molecular monitoring in chronic myeloid leukemia-how low can you go?
1Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia; School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia; School of Medicine; and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia.
Abstract:
Molecular monitoring of BCR-ABL1 transcripts for patients with chronic myeloid leukemia (CML) is now used to assess response to tyrosine kinase inhibitors (TKIs), including treatment failure that mandates a change of therapy. Therefore, many centers have adopted the molecular technique for measuring BCR-ABL1 and rely on conversion of values to the international reporting scale for appropriate clinical interpretation. However, the technique has a degree of inherent variability despite standardized procedures, which means care should be taken by the clinician when assessing response based on BCR-ABL1 cutoff limits. The last few years have witnessed the emergence of a new molecular response target, which is the achievement and maintenance of a deep molecular response. The ability to achieve treatment-free remission for some patients has shifted the relevant boundary for molecular response. However, the definitive safe BCR-ABL1 transcript level and length of the maintenance phase after which treatment cessation can be attempted has not yet been determined. For patients with TKI resistance, BCR-ABL1 kinase domain mutation analysis remains an essential assessment to guide therapy. Furthermore, low-level mutation detection is clinically relevant for response prediction to subsequent TKI therapy for some patients. Multiple low-level mutations may be a biomarker of a clonally diverse disease with the propensity for resistance evolution. Overall, molecular monitoring, including low-level monitoring is a fundamental component of management for patients with CML.
Insights
Molecular monitoring of BCR-ABL1 transcripts is crucial for chronic myeloid leukemia (CML) patients on tyrosine kinase inhibitors (TKIs). This includes assessing treatment response, guiding therapy changes, and exploring deep molecular response for potential treatment-free remission.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Molecular monitoring of BCR-ABL1 transcripts is standard for assessing chronic myeloid leukemia (CML) treatment response to tyrosine kinase inhibitors (TKIs).
- Standardized procedures exist, but inherent variability necessitates careful clinical interpretation of BCR-ABL1 levels.
- Deep molecular response is a newer target, influencing treatment-free remission strategies.
Purpose of the Study:
- To review the role and nuances of molecular monitoring in CML management.
- To highlight the importance of BCR-ABL1 transcript level interpretation and variability.
- To discuss the evolving landscape of molecular response targets and mutation analysis.
Main Methods:
- Review of current molecular monitoring techniques for BCR-ABL1.
- Analysis of BCR-ABL1 transcript variability and clinical interpretation.
- Discussion of deep molecular response and treatment-free remission criteria.
- Evaluation of BCR-ABL1 kinase domain mutation analysis for TKI resistance.
Main Results:
- Molecular monitoring is essential for TKI response assessment and guides therapy changes.
- Variability in BCR-ABL1 measurements requires cautious interpretation by clinicians.
- Deep molecular response is a key goal, but definitive criteria for treatment cessation are undetermined.
- Mutation analysis is vital for TKI resistance, and low-level mutations may predict response and disease evolution.
Conclusions:
- Molecular monitoring, including low-level analysis, is fundamental in CML patient management.
- Accurate interpretation of BCR-ABL1 levels and mutation status is critical for optimizing therapy.
- Further research is needed to define safe parameters for treatment cessation aiming for remission.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016